12.01.09 18:32 Age: 2 yrs
In 2008, Ipsogen reinforced its leadership in molecular diagnosis and monitoring of leukemia
Category: Leukemia
During the last quarter of 2008, Ipsogen launched three new molecular diagnostic kits
Marseille, Jan. 12, 2009 - IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a cancer profiler that develops and markets molecular diagnostic products for leukemia and breast cancer has launched 3 new products during the fourth quarter of 2008, that expand its leukemia molecular diagnostic portfolio:
- FusionQuant® BCR-ABL IVD kit, used in the the detection and monitoring of chronic myeloid leukemias (CML), is a new CE marked expanded version of our existing product. The new IVD kit now provides all the necessary components in one package adding convenience and efficiency in the lab. The improved kit will also support the much needed test standardisation required for proper disease monitoring.
- ProfileQuant® CLLU1, in chronic lymphocytic leukemia (CLL). This research kit provides prognostic information, and has the potential to play a significant role in the monitoring of this disease.
- MutaScreen™ MPL, a research kit for the detection of MPL mutations in JAK2 negative myeloproliferative neoplams (MPN), is a significant addition to the MPD family of products that Ipsogen offers.
These 3 new tests exemplify Ipsogen’s strategy of (i) introducing technological and scientific innovation to address unmet diagnostic needs, and (ii) rapidly translating scientific discoveries into patient bedside tools, in line with the ultimate objective of enabling better and more personalised disease management.
“In the last quarter of 2008, we launched 3 new products. With 21 kits now in distribution, of which 10 are CE marked, Ipsogen’s molecular diagnostic portfolio covers a significant range of the leukemia spectrum. These new products will help hematologists refine and improve treatment strategies” says Stephane Debono, COO and in charge of product planning.
Vincent Fert, CEO, concludes: ‘These 3 new product launches are in line with our 2008 plans, and will further equip our sales staff with a comprehensive and market leading range of leukemia products that helps consolidate our leadership position in this growing market’.
More
